Group 1 - The core viewpoint of the article emphasizes that Zhonghui Medical is leveraging non-invasive ultrasound technology to build a new "big health" ecosystem in China, positioning itself as a leader in this field through original research and development [1][2] - The company has made significant advancements over the past decade, evolving its technology from a high-intensity focused ultrasound tumor treatment system to a dual-energy ultrasound treatment robot, which is expected to be used for non-invasive breast tumor treatment by 2027 [1][2] - Zhonghui Medical is not just a device manufacturer but is also focused on implementing non-invasive concepts and ecosystems, utilizing cutting-edge technology combined with remote collaboration to enhance healthcare accessibility [2] Group 2 - The company has established partnerships with over 20 top-tier hospitals and several universities, working on integrated "production, learning, research, and application" to overcome industry bottlenecks and ensure regulatory compliance [2] - Current products are covered by medical insurance, allowing patients to pay only 20%-30% of the costs for treatments related to liver cancer and uterine fibroids, thus democratizing access to advanced medical technologies [2] - Zhonghui Medical is expanding its non-invasive ultrasound ecosystem into pet healthcare and aesthetic medicine, with commercialized products already in major cities and ongoing clinical research collaborations [2] Group 3 - The company is accelerating its international expansion under the "Belt and Road" initiative, aiming to establish "Chinese standards" in the global non-invasive medical market while pursuing EU certification [2][3] - Challenges include the need for continuous clinical data accumulation and grassroots market education, but the company remains committed to deepening its focus on non-invasive technologies and promoting quality healthcare resources [3] - With rapid technological advancements and market support, Zhonghui Medical is transitioning from an "industry innovator" to a "global leader," showcasing the strength of Chinese medical innovation [3]